Clinical Implications of Testing HER2 and Targeted Therapies Approved - Dr. Komal Jhaveri

In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression.Key topics include:• The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options.• The definition and implications of low and ultra-low HER2 expression in clinical practice.• The importance of HER2 testing and the dynamic nature of HER2 expression in tumors.• Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan.• Management of treatment-related toxicities, including ILD, nausea, and alopecia.Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care.Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Don't forget to subscribe for more episodes and insights!#HER2low #BreastCancer #DestinyTrials #ADC #OncologyBrothers #MetastaticBC